Novogen Limited Stock Australian S.E.
Stocks
AU000000NRT0
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 183M 127M 113M 105M 96.02M 181M 12.21B 1.27B 494M 6.24B 477M 467M 20.04B | P/E 2026 * |
-5.63x | P/E 2027 * | -6.79x |
|---|---|---|---|---|---|
| Enterprise Value | 183M 127M 113M 105M 96.02M 181M 12.21B 1.27B 494M 6.24B 477M 467M 20.04B | EV / Sales 2026 * |
270x | EV / Sales 2027 * | 285x |
| Free-Float |
45.6% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Novogen Limited
| 1 day | -89.73% |
| Manager | Title | Age | Since |
|---|---|---|---|
John Friend
CEO | Chief Executive Officer | 56 | 2023-04-30 |
James Levine
DFI | Director of Finance/CFO | 55 | 2026-05-31 |
Sudha Rao
CTO | Chief Tech/Sci/R&D Officer | - | 2026-04-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Steven Coffey
BRD | Director/Board Member | 65 | 2012-11-05 |
John Friend
CHM | Chairman | 56 | 2023-08-10 |
Ebru Davidson
BRD | Director/Board Member | - | 2023-06-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -89.73% | -7.32% | - | - | 127M | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +20.19% | +79.01% | 57.39B | |
| +0.89% | -0.63% | +2.17% | +35.99% | 47.64B | |
| +0.36% | +0.81% | +342.39% | +748.97% | 44.29B | |
| -0.96% | -4.50% | +24.96% | +31.45% | 42.5B | |
| -0.20% | -0.77% | +4.13% | +111.69% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +54.06% | 30.97B | |
| +1.92% | +4.12% | +32.38% | +29.60% | 28.53B | |
| +0.05% | -1.64% | -8.14% | -12.10% | 24.34B | |
| Average | -8.72% | -0.59% | +52.97% | +130.32% | 43.39B | |
| Weighted average by Cap. | +0.43% | -0.84% | +57.18% | +139.59% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 677K 471K 418K 390K 356K 671K 45.23M 4.72M 1.83M 23.12M 1.77M 1.73M 74.21M | 642K 446K 396K 370K 337K 636K 42.89M 4.48M 1.74M 21.93M 1.68M 1.64M 70.38M |
| Net income | -24.51M -17.03M -15.13M -14.13M -12.88M -24.28M -1.64B -171M -66.24M -837M -63.95M -62.57M -2.69B | -30.84M -21.43M -19.04M -17.77M -16.2M -30.55M -2.06B -215M -83.35M -1.05B -80.47M -78.72M -3.38B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
